Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Biologicals"

44 News Found

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


B Medical Systems to invest Rs 100 cr. to manufacture medical cold chain equipment in Gujarat
Medical Device | December 09, 2021

B Medical Systems to invest Rs 100 cr. to manufacture medical cold chain equipment in Gujarat

An MoU was signed between B Medical Systems and Gujarat government recently


Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin
Biotech | November 05, 2021

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin

The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent


Cadila Healthcare signs agreement with Shilpa Medicare for production of ZyCoV-D
News | September 26, 2021

Cadila Healthcare signs agreement with Shilpa Medicare for production of ZyCoV-D

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus


Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
Policy | August 06, 2021

Govt augments PSEs and Bharat Biotech to ramp up Covaxin production

CDSCO to fast-track trials and approval for COVID19 vaccine


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | August 03, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | July 28, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks
News | July 28, 2021

Morepen to start Sputnik V Vaccine commercial production in 4-6 weeks

The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval


RDIF and Morepen announce production of test batch of Sputnik V
News | July 08, 2021

RDIF and Morepen announce production of test batch of Sputnik V

The first batch will be shipped to the Gamaleya Center for the quality control


Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
News | May 18, 2021

Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine

Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production